ClinicalTrials.gg
RecruitingNCT07454382Updated Jun 16, 2026

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

A Phase 2 interventional study of Elranatamab-bcmm and Cyclophosphamide in Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 171 studies testing cyclophosphamide in Multiple Myeloma — 15 open to participants now, 27 under way, 1 of them phase 3. Cyclophosphamide · Multiple Myeloma.

Planned enrollment
111th of 167
26 · median 41
Started
2026
with 1 other
Phase 2
92 of 171
8 open now
Primary completion
2029-08
later than 23 of 26 live
Registered
171st of 171
by date

Among the 171 studies testing cyclophosphamide in Multiple Myeloma, this one is the 111th largest by planned enrollment of the 167 interventional ones that give a count, is one of 2 that started in 2026, is one of 92 in phase 2, reaches primary completion later than 23 of the 26 other live ones, and was the 171st registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 171 studies testing cyclophosphamide in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies testing cyclophosphamide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Memorial Sloan Kettering Cancer Center
  • 26-006
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documentation of Disease:

    • Patients must have confirmed diagnosis of multiple myeloma (MM) as defined according to 2014 IMWG criteria.
    • defined by at least 1 of the following:
    • Serum M-protein ≥0.5 g/dL by SPEP
    • Serum immunoglobulin free light chain ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (\<0.26 or >1.65)
    • Urinary M-protein excretion ≥200 mg/24 hours by UPEP
    • Bone marrow plasma cell percentage (in aspirate or , whichever is higher) of ≥30%
    • Myeloma bone lesion or plasmacytoma lesion with a single diameter of ≥2 cm
  • Adverse risk features defined as having ≥1 of the following:

    • Presence of extramedullary myeloma identifiable by 18F-FDG PET/CT
    • Serum beta-2-microglobulin (B2M) level ≥5.5 mg/dL
    • Bone marrow plasma cell percentage (in aspirate or biopsy, whichever is higher) of ≥50%
  • Prior Treatment Exposure:

    • Participants have received at least 1 for MM including:
  • At least 1 IMiD (thalidomide, lenalidomide or pomalidomide)
  • At least 1 PI (bortezomib, carfilzomib or ixazomib)
  • At least 1 anti-CD38 monoclonal antibody (daratumumab or isatuximab)
  • Age ≥ 18
  • Performance Status ≤ 2 (See Appendix I for performance status criteria)
  • Not Pregnant and Not Nursing

    • The effects of elranatamab and cyclophosphamide on the developing human fetus are unknown. For this reason and because cyclophosphamide as well as other therapeutic agents used in this trial are known to be teratogenic, participants of must agree to use adequate (hormonal or barrier method of birth control; abstinence) during study therapy and for 6 months following the completion of study therapy. Should a participant become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately.
  • Required Organ Function:

    • Adequate hematologic function defined as follows:
  • (ANC) ≥ 1,000 cells/mm3(use of G-CSF is permitted if completed at ≥7 days prior to planned start of study treatment)
  • ≥ 25,000 cells/mm3 (transfusion support is permitted)
  • ≥ 8 g/dl (transfusion support is permitted)

    • Adequate renal function defined as follows:
  • (CrCL) of ≥15 mL/min by the formula, Cockcroft-Gault formula, or with direct measurement.

    • Adequate hepatic function defined as follows:
  • Total ≤ 1.5 x institutional (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled)
  • and ALT ≤3 x institutional ULN

    • Adequate cardiac function defined as follows:
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function (see exclusionary cardiac conditions below)

Exclusion criteria

Exclusion Criteria:

  • Exclusionary Prior Treatments, Diagnoses and Comorbid Conditions

    • Previous treatment with a CD3 redirecting bispecific or trispecific antibody for multiple myeloma.
    • Plasma cell leukemia (as defined by the IMWG49), smoldering multiple myeloma, Waldenström's macroglobulinemia, amyloidosis, or POEMS syndrome.
    • Active central nervous system involvement or clinical signs of myelomatous meningeal involvement.
    • History of stem cell transplant within 8 weeks prior to enrollment.
    • Active or history of allogeneic stem cell transplant within 12 weeks prior to enrollment.
    • cardiovascular diseases, defined as any of the following within 6 months prior to enrollment:
  • Acute myocardial infarction, acute coronary syndromes (e.g., unstable angina, coronary artery bypass graft, coronary angioplasty or stenting, pericardial effusion)
  • Clinically significant cardiac arrhythmias (e.g., uncontrolled atrial fibrillation, uncontrolled paroxysmal supraventricular tachycardia, or ventricular tachycardia)
  • Decompensated heart failure syndrome. To be eligible for this trial, patients should be class 2B or better (see Appendix II: (NYHA) Functional Classification).
  • Thromboembolic or cerebrovascular events (e.g., , cerebrovascular accident, or pulmonary embolism with evidence of right heart strain)
  • Prolonged syndrome (or QTcF >470 msec at screening).
  • Active or uncontrolled bacterial, , , , SARS-CoV-2, other viral, or fungal infections. Acute bacterial, viral, or fungal infections must be resolved prior to enrollment. Specific considerations for certain infections listed below:

    • HIV
    • HIV seropositive participants who are otherwise healthy and at low risk for AIDS-related outcomes could be considered eligible. Potential eligibility for a specific HIV-positive protocol candidate should be evaluated and discussed with the investigator prior to any screening, based on current and past CD4 and T-cell counts, history (if any) of AIDS defining conditions (e.g., opportunistic infections), and status of HIV treatment.
    • HBV
    • Participants with positive HBsAg or detectable HBV DNA may be permitted provided they have been taking appropriate anti-viral medication (e.g. entecavir, tenofovir) for at least 28 days prior to enrollment, willing to continue therapy, and with screening HBV DNA is \<2 × 10³ IU/mL, without evidence of hepatic decompensation. Participants with negative HBsAg but positive anti-HBc antibody, indicating immunity from prior natural infection, are eligible provided their screening HBV DNA is \<2 × 10³ IU/mL, they are willing to take an appropriate anti-viral medication and undergo HBV DNA monitoring during the study.
    • HCV
    • Positive HCV antibody is indicative of prior infection but may not necessarily render a potential participant ineligible. If exposure to HCV is recent, the HCV antibody test may not yet be positive. In this case, testing for HCV RNA is recommended. Patients with a positive HCV antibody must undergo HCV RNA PCR, and those with detectable HCV RNA will be excluded.
    • COVID-19/SARS-CoV-2
    • COVID-19/SARS-CoV-2: COVID-19/SARS-CoV-2 PCR testing of nasopharyngynx is mandated at the screening visit. Participants with a positive PCR test result within 7 days prior to enrollment or those suspected of having an active COVID-19/SARS-CoV-2 infection will be excluded from study enrollment.
  • Any other active within 2 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ, Stage 0/1 malignancy with minimal risk of recurrence, or low risk neoplasm that does not require active therapy and has demonstrated stability over a 2-year surveillance period.
  • History of Guillain-Barré syndrome (GBS) or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy.
  • History of organ transplant requiring therapy.
  • Gastrointestinal conditions that would alter the absorption of cyclophosphamide.
  • Other surgical (including major surgery within 14 days prior to enrollment), medical or psychiatric conditions including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • History of anaphylaxis or severe to cyclophosphamide.
  • Receipt of a within 4 weeks of the first dose of study intervention.
  • Receipt of a cumulative dose of equivalent to ≥140 mg of prednisone within the 14-day period before the first dose of study intervention.
  • Participant unable or unwilling to undergo protocol required anti-infection prophylaxis.
  • Previous administration with an product (drug or vaccine) within 28 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is shorter). A participant may be eligible even if they are in the follow-up phase of an investigational study if they meet the criterion for time elapsed from previous administration of investigational product. Cases must be discussed with the investigator to judge eligibility.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Participants with Multiple Myeloma

    Participants must have pathologically confirmed diagnosis of multiple myeloma (MM) as defined according to 2014 IMWG criteria

    Biological: Elranatamab-bcmm · Drug: Cyclophosphamide

Interventions

  • BiologicalElranatamabStudies of ElranatamabElranatamab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Elranatamab-bcmm is a recombinant, humanized, bispecific IgG2 kappa antibody

  • Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards

06

What researchers measure

Primary outcomes

  1. Complete response rate

    To evaluate the complete response rate of elranatamab with cyclophosphamide in participants with relapsed or refractory multiple myeloma with adverse risk factors.

    Time frame: 6 months

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Alexander Lesokhin, MD · Contact646-608-3717
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Alexander Lesokhin, MD · Contact646-608-3717
  • Memorial Sloan Kettering Bergen (All Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Alexander Lesokhin, MD · Contact646-608-3717
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Alexander Lesokhin, MD · Contact646-608-3717
  • Memorial Sloan Kettering Westchester (All Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Alexander Lesokhin, MD · Contact646-608-3717
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Alexander Lesokhin, MD · Contact646-608-3717
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Alexander Lesokhin, MD · Contact646-608-3717
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2029, 42 months after the start.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 42 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 6, 2026
StartActual
Feb 27, 2026
Primary completionEst.
Aug 27, 2029
CompletionEst.
Aug 27, 2029
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454382
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Feb 27, 2026
Primary completion
Aug 27, 2029 (estimated)
Completion
Aug 27, 2029 (estimated)
Last update
Jun 16, 2026

Study contacts

Alexander Lesokhin, MD
Contact
lesokhia@mskcc.org
646-608-3717
Carlyn Rose Tan, MD
Contact
TanC4@mskcc.org
646-608-3778
Alexander Lesokhin, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclophosphamide

Start the discussion